A new Philadelphia Business Journal article explains how in addition to being a hub for cell and gene therapy, the Philadelphia area is beginning to emerge as an active player in the field of gene editing.
The article mentions several examples of Philadelphia-based gene editing companies, including Penn spinout iECURE, inc. iEcure is about to file its first investigational new drug application for its flagship gene-editing treatment, GTP-506. If approved, iEcure will be able to begin human testing of the treatment, which is being developed to treat ornithine transcarbamylase (OTC) deficiency, a genetic disorder that affects the central nervous system. Read more here.